Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance
Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, double-blind and randomized placebo controlled trial
for evaluation of a 7-day 100mg daily dose of spironolactone on weight loss and resolution of
signs and symptoms of congestion in outpatients with acute decompensated heart failure
(ADHF). Patients who are not responding to their current loop diuretics will be considered
for this study. Mineralocorticoid receptor antagonists (MRAs) are recommended as standard of
care in management of heart failure (HF) patients. However, recommended doses of MRAs
(spironolactone 25mg/daily or eplerenone 50mg/daily) will not have any impact on signs and
symptoms of volume overload. Therefore, the proposed study will aim to show the impact of
this outpatient regimen to improve diuresis and possible reduction in hospitalization for
further diuretic management in HF patients with signs and symptoms of congestion.